Form 4: Amylyx Pharmaceuticals Co-CEO Justin B. Klee Receives Stock Awards

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, reports the acquisition of restricted stock units and stock options.

Summary

• Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 26, 2024, Klee acquired 126,667 shares of common stock through a restricted stock unit (RSU) award.
• The RSU will vest in four equal annual installments, starting one year from the grant date, contingent on continued service.
• Klee also acquired options to purchase 190,000 shares of common stock at an exercise price of $17.56.
• These options vest over 48 months, with the first 25% vesting one year from the grant date and the remainder vesting monthly thereafter, also contingent on continued service.
• Following these transactions, Klee directly owns 2,963,443 shares of Amylyx Pharmaceuticals.
• Klee also directly owns 190,000 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. It's a neutral-positive signal.

Positives

• The grant of RSUs and stock options to the Co-CEO aligns his interests with those of the shareholders.
• The vesting schedules of the RSUs and stock options incentivize continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Biogen and Vertex Pharmaceuticals also utilize similar equity-based compensation to align executive incentives with shareholder value.
• The vesting schedules described are typical for such grants, encouraging long-term commitment from the executive.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates